While enhanced expression of CLDN4 in luminal breast cancers was linked to poor clinical outcomes, contrastingly, overexpression of CLDN4 in TNBC was associated with favorable outcomes in which tumors that overexpressed CLDN4 displayed a less aggressive phenotype [53]. This evidence concerns the gene CLDN4 and breast cancer.